inhibitor

(redirected from reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to reverse transcriptase inhibitor: NNRTI, NRTI
See: deterrent
References in periodicals archive ?
Merck also intends to commence with a Phase II study of MK-1439, an investigational next generation non-nucleoside reverse transcriptase inhibitor.
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a non-nucleoside reverse transcriptase inhibitor with both early (OR 4.
Four-hundred and forty-seven HIV-1 infected patients have received combination therapy with Emtriva and Viread with either a non-nucleoside reverse transcriptase inhibitor (Study 934) or protease inhibitor for 48 weeks in clinical studies.
based in Research Triangle Park, NC, for CMX157, an investigational oral nucleoside reverse transcriptase inhibitor currently in Phase I clinical development.
Adults: The recommended dosage of SUSTIVA is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Have failed at least 2 protease inhibitors or 1 protease inhibitor and a non-nucleoside reverse transcriptase inhibitor (i.
Tenofovir, Gilead Sciences' candidate reverse transcriptase inhibitor, could be approved in about six months.
Fischer was Senior Vice President of Dupont Pharmaceuticals/Dupont-Merck's Virology Franchise, where he was responsible for the product launch of the HIV non-nucleoside reverse transcriptase inhibitor SUSTIVA.
They then added nevirapine (Viramune) and at least 1 nucleoside reverse transcriptase inhibitor (NRTI).
The product contains 600 mg of efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, both nucleoside reverse transcriptase inhibitors (NRTIs).
Patients must also have failed treatment with at least two protease inhibitors (PIs) or one PI and one non nucleoside analog reverse transcriptase inhibitor.
Yesterday, October 31, 00, FDA approved a new formulation of the nucleoside reverse transcriptase inhibitor, ddI, called VIDEX EC.

Full browser ?